StockNews.com Begins Coverage on ObsEva (NASDAQ:OBSV)

StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV) in a research report released on Wednesday. The firm issued a hold rating on the stock.

ObsEva Stock Performance

Shares of NASDAQ:OBSV opened at $0.01 on Wednesday. The stock has a market capitalization of $974,637.50, a PE ratio of -0.01 and a beta of 0.68. ObsEva has a 1 year low of $0.08 and a 1 year high of $2.14. The firm has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.05.

Institutional Investors Weigh In On ObsEva

Several hedge funds have recently made changes to their positions in the stock. Credit Suisse AG lifted its stake in ObsEva by 11.0% during the fourth quarter. Credit Suisse AG now owns 1,750,573 shares of the company’s stock worth $255,000 after purchasing an additional 173,455 shares during the period. Bank of America Corp DE lifted its stake in ObsEva by 54,142.2% during the first quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock worth $731,000 after purchasing an additional 483,490 shares during the period. Two Sigma Investments LP bought a new position in shares of ObsEva in the third quarter valued at approximately $25,000. Millennium Management LLC bought a new position in shares of ObsEva in the second quarter valued at approximately $192,000. Finally, XTX Topco Ltd raised its stake in shares of ObsEva by 33.9% in the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after acquiring an additional 20,196 shares during the last quarter. Institutional investors own 17.52% of the company’s stock.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.